Home » Stocks » ATRA

Atara Biotherapeutics, Inc. (ATRA)

Stock Price: $12.65 USD -0.12 (-0.94%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $12.70 +0.05 (0.40%) Jul 26, 4:53 PM
Market Cap 1.06B
Revenue (ttm) 3.55M
Net Income (ttm) -311.45M
Shares Out 91.46M
EPS (ttm) -3.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $12.65
Previous Close $12.77
Change ($) -0.12
Change (%) -0.94%
Day's Open 12.78
Day's Range 12.56 - 12.94
Day's Volume 376,723
52-Week Range 11.33 - 28.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

3 weeks ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

3 weeks ago - Business Wire

Why there is opportunity in biotech and the names to watch

YouTube video

Kevin Mahn, Hennion and Walsh chief investment officer, joins 'The Exchange' to discuss the names he's favoring in the pharma sector. For access to live and exclusive video from CNBC subscribe to CNBC P...

Other stocks mentioned: BLUE, IBB, SRPT
1 month ago - CNBC Television

Atara Biotherapeutics Inc (NASDAQ: ATRA) has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel (tab-cel) in patients with Epstein-Barr virus-driven post-t...

1 month ago - Benzinga

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

1 month ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformativ...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

2 months ago - Business Wire

These seven stocks may be risky, but they also have the potential for big returns -- as all of them are stocks that could double by summer. The post 7 Stocks That Could Double by Summer appeared first o...

Other stocks mentioned: BLI, CGEN, CIDM, CRDF, KERN, ZDGE
3 months ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

3 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop ...

6 months ago - Business Wire

A Relative Strength Rating upgrade for Atara Biotherapeutics shows improving technical performance. The post Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating appeared first on...

6 months ago - Investors Business Daily

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformativ...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop ...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative...

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative ...

7 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

7 months ago - Business Wire

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and...

7 months ago - Business Wire

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mont...

Other stocks mentioned: ALLO, BMY, CLLS, CRSP, GILD, NVS, PFE
7 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

8 months ago - Business Wire

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative...

8 months ago - Business Wire

Atara Biotherapeutics sees its Relative Strength Rating reach the elite 90-plus level.

10 months ago - Investors Business Daily

24/7 Wall St. reviews dozens of analyst research reports each day of the week, and most of the so-called Buy and Outperform ratings come with upside of 8% to 10% for Dow Jones industrials, S&P 500 and r...

10 months ago - 24/7 Wall Street

Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXP, FVRR, HD, JNJ, JPM, KO ...
10 months ago - Seeking Alpha

Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

10 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

10 months ago - Business Wire

When it comes to life-threatening illnesses, mesothelioma would rank close to the top of the list.

10 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

10 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

10 months ago - Business Wire

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

11 months ago - Business Wire

Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

11 months ago - Business Wire

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

About ATRA

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies a... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2014
CEO
Pascal Touchon
Employees
480
Stock Exchange
NASDAQ
Ticker Symbol
ATRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is 35.29, which is an increase of 178.97% from the latest price.

Price Target
$35.29
(178.97% upside)
Analyst Consensus: Buy